Search

days

 

The 24th CHINA-PHARM & 85th API China:

All rights reserved ©  Reed Sinopharm Exhibitions Co., Ltd.    京ICP备06050757号                                                                                    Website building:Powered By 300.cn Beijing

International Sales and marketing:

Evan Wang 010-84556692

Linkedin

 Mobile

新闻中心

News

Pharmaceutical Production and Marketing Report Series 3: Production of Chemical Pharmaceutical Industry

Source:
2020/08/28 15:27
[Abstract]:

II. Output and Export Volume of Major APIs

1. Anti-infective Drugs

The output of anti-infective drugs in 2019 Q1 increased by 5.6% year on year, the output in the first half year increased by 2.8%, and the annual output increased by 1.8%. The output of penicillins increased by 11.1% year on year and its export increased by 19.6%. The output of cephalosporins decreased by 2.2% and its export increased by 22%. The output of aminoglycosides increased by 39.5% and its export increased by 15.3%, among which, the output and export of neomycin sulphate produced by Yichang Sanxia Pharmaceutical doubled year on year. The output of anti-tuberculous drugs increased by 43.3% and its export increased by 10%. Rifampicin produced by Shenyang Antibiotic Manufacturer increased by 176.3% year on year. The output and export of streptomycin sulfate produced by North China Pharmaceutical Co., Ltd. increased by over 20%. The output of dihydrostreptomycin sulphate increased by 44% year on year and its export increased by 11.9%. The output and export of tetracycline, amide alcohol, macrolide, quinolone and antifungal drugs decreased year on year. The output of amide alcohol decreased by 47.5% and its export decreased by 19.5%.  The output of ahloramphenicol produced by Northeast Pharm decreased by 40% and its export decreased by 18.3% year on year.

 

 

(1) Penicillin

The output of penicillin in 2019 increased by 11.1% year on year and its exports increased by 11.1%. The output of amoxicillin increased by 10.4% year on year and its export increased by 12.3%. Amoxicillin sodium produced by Harbin Pharmaceutical Group General Pharmaceutical and Brilliant Pharmaceutical experienced a year-on-year output decline, while the output of other companies gained a year-on-year increase. The output and export of North China Pharmaceuticals both increased by over 20%. The output of United Laboratories Inner Mongolia and Zhuhai increased by 6.3% year on year. The output of penicillin sodium increased by 24.8% year on year. Among its four manufacturers, the output of Harbin Pharmaceutical Group General Pharmaceutical remained stable; the output of Jiangxi Dongfeng Pharmaceutical decreased by 49.6% year on year due to market factors; the output of CSPC and LKPC increased by over 40% year on year. The output of piperacillin produced by Shandong Ruiying Pioneer Pharmaceutical increased by 65.8% year on year.

 

 

(2) Cephalosporins

The output of cephalosporin decreased by 5.1% in 2019 Q1, 1.5% in 2019 Q2, and 2.2% in the whole year. Its exports increased by 22% year on year. A total of 34 cephalosporin varieties were produced in 2019, among which 21 varieties showed a year-on-year decrease in output, and 11 varieties showed a decrease of more than 30%. 13 cephalosporin drugs achieved an output over 100 tons, and 6 ones were included in the National Essential Drugs List. The most productive ceftriaxone sodium experienced a year-on-year output decrease of 3.2%. Among the 9 manufacturers, 7 ones produced more than 100 tons, among which 4 manufacturers experienced a year-on-year decrease and the other 3 ones gained an increase. The output of cephalexin decreased by 7.8%. The output and export of cefazolin sodium increased by over 40%, and the output of all the 5 manufacturers increased year on year.

 

For business, plz contact:

Mr. Evan

Tel: +86 010 8455 6692

Mob: +86 185 1324 5331 (WeChat & Whatsapp)

Email:ye.wang@reedsinopharm.com